The Food and Drug Administration (FDA) has approved Dayvigo (lemborexant; Eisai) for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adult patients.
Although higher nurse-to-patient ratios ensure good outcomes for patients undergoing pancreaticoduodenectomy, PD-specific surgeon volume has a greater effect on risks of complications for these patients.
Pancreatic enzyme replacement therapy (PERT) increased body weight of individuals with pancreatic exocrine insufficiency (PEI) following pancreatoduodenectomy as compared with placebo; however, the effect was not significant.
The study researchers concluded that endoscopic biliary drainage with temporary FCSEMS placement be considered a first-line therapy for CP-associated BBS, and that surgery should still be considered in patients who fail stricture resolution following 1 year indwell.
Pancreatic calcifications are associated with diverse etiological risk factors in patients with chronic pancreatitis (CP), attesting to the complexity of CP as a disease, and possibly having implications for disease classification.